Open AccessTargeting valosin‐containing protein enhances the efficacy of radiation therapy in esophageal squamous cell carcinoma
Author(s) -
Luo Hui,
Song Hengli,
Mao Ronghu,
Gao Qiang,
Feng Zhuo,
Wang Nan,
Song Shuai,
Jiao Ruidi,
Ni Peizan,
Ge Hong
Publication year - 2019
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.14184
Subject(s) - medicine , cancer research , radiation therapy , apoptosis , unfolded protein response , cell , esophageal cancer , immunohistochemistry , cell growth , cell culture , cancer , biology , biochemistry , genetics
Overcoming resistance to radiation is a great challenge in cancer therapy. Here, we highlight that targeting valosin‐containing protein ( VCP ) improves radiation sensitivity in esophageal squamous cell carcinoma ( ESCC ) cell lines and show the potential of using VCP as a prognosis marker in locally advanced ESCC treated with radiation therapy. Esophageal squamous cell carcinoma cell lines with high VCP expression were treated with VCP inhibitor combined with radiotherapy. Cell proliferation, colony formation, cell death, and endoplasmic reticulum ( ER ) stress signaling were evaluated. Moreover, patients with newly diagnosed locally advanced ESCC who were treated with radiotherapy were analyzed. Immunohistochemistry was used to detect the expression of VCP . The correlation between overall survival and VCP was investigated. Esophageal squamous cell carcinoma cells treated with VCP inhibitor and radiotherapy showed attenuated cell proliferation and colony formation and enhanced apoptosis. Further investigation showed this combined strategy activated the ER stress signaling involved in unfolded protein response, and inhibited the ER ‐associated degradation ( ERAD ) pathway. Clinical analysis revealed a significant survival benefit in the low VCP expression group. Targeting VCP resulted in antitumor activity and enhanced the efficacy of radiation therapy in ESCC cells in vitro. Valosin‐containing protein is a promising and novel target. In patients with locally advanced ESCC who received radiotherapy, VCP can be considered as a useful prognostic indicator of overall survival. Valosin‐containing protein inhibitors could be developed for use as effective cancer therapies, in combination with radiation therapy.